Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Equity Ratio (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Equity Ratio for 4 consecutive years, with 1.21 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio fell 91.41% year-over-year to 1.21, compared with a TTM value of 1.21 through Sep 2025, down 91.41%, and an annual FY2024 reading of 0.89, down 48.72% over the prior year.
  • Equity Ratio was 1.21 for Q3 2025 at Atara Biotherapeutics, down from 0.95 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.59 in Q2 2022 and bottomed at 1.21 in Q3 2025.
  • Average Equity Ratio over 4 years is 0.32, with a median of 0.59 recorded in 2024.
  • The sharpest move saw Equity Ratio tumbled 3225.27% in 2024, then decreased 0.45% in 2025.
  • Year by year, Equity Ratio stood at 0.34 in 2022, then crashed by 278.21% to 0.6 in 2023, then plummeted by 48.72% to 0.89 in 2024, then crashed by 36.19% to 1.21 in 2025.
  • Business Quant data shows Equity Ratio for ATRA at 1.21 in Q3 2025, 0.95 in Q2 2025, and 0.89 in Q1 2025.